MDGL Madrigal Pharmaceuticals Stock Outlook 2026: Rezdiffra's First-Mover Lead vs. GLP-1 Competition
Madrigal Pharmaceuticals (MDGL) 2026 stock analysis: Rezdiffra revenue trajectory reaching $958M in FY2025 and $311M in Q1 2026, US payer coverage progress, GLP-1 competition dynamics, confirmatory trial risk, and acquisition thesis.
MDGL Madrigal Pharmaceuticals Rezdiffra